代谢功能障碍相关脂肪性肝病与心力衰竭风险:全国性队列研究
该研究基于韩国全国健康保险服务筛查队列218 605名成年人,分析MASLD与心力衰竭发病的关联。中位随访9.6年发生16 340例心衰,MASLD患者心衰风险显著升高(调整HR 2.62,95%CI 2.39-2.86),且风险随CMRF数量增加而递增。结论认为MASLD独立于传统心血管代谢危险因素与心衰发病相关。
要点
- MASLD患者心衰风险是无MASLD且无CMRF者的2.62倍(调整HR 2.62,95%CI 2.39-2.86)。
- 每增加一个CMRF,心衰风险增加24%(调整HR 1.24,95%CI 1.22-1.25)。
- MASLD可能应纳入未来心衰风险分层考量。
核心结论
- MASLD独立于传统心血管代谢危险因素与心力衰竭发病相关。
研究设计与样本
- 韩国全国健康保险服务筛查队列研究,纳入2009至2010年218 605名成年人,排除其他肝病、过量饮酒、癌症、肝硬化及数据缺失者。
- MASLD定义为脂肪肝指数≥30且至少合并一个CMRF,随访至2019年,使用多变量调整Cox比例风险模型估计调整HR。
主要发现
- 218 605名参与者中32%患有MASLD,其心血管代谢特征较无脂肪性肝病者更差。
- 中位随访9.6年期间发生16 340例心力衰竭。
- MASLD患者心衰风险显著高于无脂肪性肝病且无CMRF者(调整HR 2.62,95%CI 2.39-2.86)。
- 心衰风险随CMRF数量增加而递增(每增加一个CMRF:调整HR 1.24,95%CI 1.22-1.25)。
临床怎么用
- 对MASLD患者应关注心衰风险,尤其合并多个心血管代谢危险因素时。
- MASLD可考虑作为心衰风险分层的额外参考因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) shares metabolic and inflammatory pathways with heart failure. However, prior studies with small samples and broad cardiometabolic risk factor (CMRF) groupings have left the relationship unclear. We aimed to assess the independent effect of MASLD and the combined impact of specific CMRFs on heart failure incidence. METHODS: We analysed data from 218 605 adults in the Korean National Health Insurance Service screening cohort between 2009 and 2010, excluding those with other liver diseases, excessive alcohol use, cancer, cirrhosis or missing data. MASLD was defined based on a Fatty Liver Index ≥30 with at least one CMRF. Participants were categorised by MASLD and CMRF status, and incident heart failure was identified during follow-up until 2019. Adjusted HRs were estimated using multivariable adjusted Cox proportional hazards models. RESULTS: Among the 218 605 participants, 32% had MASLD with less favourable cardiometabolic profiles than those without steatotic liver disease. During a median follow-up of 9.6 years, 16 340 incident heart failure cases occurred. Patients with MASLD had a significantly higher risk of heart failure than individuals without steatotic liver disease and CMRFs (adjusted HR 2.62, 95% CI 2.39 to 2.86). Heart failure risk increased progressively with an increasing number of CMRFs (per additional CMRF: adjusted HR 1.24, 95% CI 1.22 to 1.25). CONCLUSIONS: MASLD is independently associated with incident heart failure beyond traditional CMRFs. Therefore, MASLD's role may warrant consideration in future heart failure risk stratification.
引用
- Kim, Jo, Ha, et al. Metabolic dysfunction-associated steatotic liver disease and risk of heart failure: a nationwide cohort study. Heart. 2025. PMID: 41402040. doi:10.1136/heartjnl-2025-327102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。